Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium. A phase II study of the Gynecologic Oncology group.
Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Twelve had received prior chemotherapy. Seven patients had stable disease; 14 had increasing disease. There were two life-threatening toxic episodes. Aminothiadiazole used in this dosage and schedule has negligible activity in previously treated patients with carcinoma of the endometrium.
University of Rochester School of Medicine, NY.
R F
RF
Asbury
J A
JA
Blessing
W P
WP
McGuire
P
P
Hanjani
R
R
Mortel
D000230:Adenocarcinoma / Q000188:drug therapy; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D013830:Thiadiazoles / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D013830:Thiadiazoles; C010852:2-amino-1,3,4-thiadiazole